173 related articles for article (PubMed ID: 21738405)
41. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.
Eiber M; Takei T; Souvatzoglou M; Mayerhoefer ME; Fürst S; Gaertner FC; Loeffelbein DJ; Rummeny EJ; Ziegler SI; Schwaiger M; Beer AJ
J Nucl Med; 2014 Feb; 55(2):191-7. PubMed ID: 24309383
[TBL] [Abstract][Full Text] [Related]
42. Misdiagnoses of 11C-choline combined with 18F-FDG PET imaging in brain tumours.
Huang Z; Zuo C; Guan Y; Zhang Z; Liu P; Xue F; Lin X
Nucl Med Commun; 2008 Apr; 29(4):354-8. PubMed ID: 18317300
[TBL] [Abstract][Full Text] [Related]
43. Dual time point 2-[18F]fluoro-2'-deoxyglucose positron emission tomography in chronic bacterial osteomyelitis.
Sahlmann CO; Siefker U; Lehmann K; Meller J
Nucl Med Commun; 2004 Aug; 25(8):819-23. PubMed ID: 15266177
[TBL] [Abstract][Full Text] [Related]
44. Uptake of positron emission tomography tracers reflects the tumor immune status in esophageal squamous cell carcinoma.
Kuriyama K; Higuchi T; Yokobori T; Saito H; Yoshida T; Hara K; Suzuki S; Sakai M; Sohda M; Higuchi T; Tsushima Y; Asao T; Kaira K; Kuwano H; Shirabe K; Saeki H
Cancer Sci; 2020 Jun; 111(6):1969-1978. PubMed ID: 32302443
[TBL] [Abstract][Full Text] [Related]
45. Diagnostic accuracy of
He Q; Zhang L; Zhang B; Shi X; Yi C; Zhang X
BMC Cancer; 2019 Apr; 19(1):332. PubMed ID: 30961564
[TBL] [Abstract][Full Text] [Related]
46. Relationship Between Tumor Immune Markers and Fluorine-18-α-Methyltyrosine ([
Shimizu K; Kaira K; Higuchi T; Hisada T; Yokobori T; Oyama T; Asao T; Tsushima Y; Shirabe K
Mol Imaging Biol; 2020 Aug; 22(4):1078-1086. PubMed ID: 31792836
[TBL] [Abstract][Full Text] [Related]
47. Diagnosis of maxillofacial tumor with L-3-[18f]-fluoro-alpha-methyltyrosine (FMT) PET: a comparative study with FDG-PET.
Miyakubo M; Oriuchi N; Tsushima Y; Higuchi T; Koyama K; Arai K; Paudyal B; Iida Y; Hanaoka H; Ishikita T; Nakasone Y; Negishi A; Mogi K; Endo K
Ann Nucl Med; 2007 Feb; 21(2):129-35. PubMed ID: 17424980
[TBL] [Abstract][Full Text] [Related]
48. Fluoro-deoxy-glucose positron emission tomography for evaluation of indeterminate lung nodules: assigning a probability of malignancy may be preferable to binary readings.
Kim SC; Machac J; Krynyckyi BR; Knesaurek K; Krellenstein D; Schultz B; Gribetz A; DePalo L; Teirstein A; Kim CK
Ann Nucl Med; 2008 Apr; 22(3):165-70. PubMed ID: 18498030
[TBL] [Abstract][Full Text] [Related]
49. Preliminary study of 11C-choline PET/CT for T staging of locally advanced nasopharyngeal carcinoma: comparison with 18F-FDG PET/CT.
Wu HB; Wang QS; Wang MF; Zhen X; Zhou WL; Li HS
J Nucl Med; 2011 Mar; 52(3):341-6. PubMed ID: 21321282
[TBL] [Abstract][Full Text] [Related]
50. Positron emission tomography-CT imaging in guiding musculoskeletal biopsy.
O'Sullivan PJ; Rohren EM; Madewell JE
Radiol Clin North Am; 2008 May; 46(3):475-86, v. PubMed ID: 18707958
[TBL] [Abstract][Full Text] [Related]
51. A comparative study of F-18 FDG PET and 201Tl scintigraphy for detection of primary malignant bone and soft-tissue tumors.
Yamamoto Y; Kawaguchi Y; Kawase Y; Maeda Y; Nishiyama Y
Clin Nucl Med; 2011 Apr; 36(4):290-4. PubMed ID: 21368603
[TBL] [Abstract][Full Text] [Related]
52. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R
J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193
[TBL] [Abstract][Full Text] [Related]
53. Biological significance of fluorine-18-α-methyltyrosine (FAMT) uptake on PET in patients with oesophageal cancer.
Suzuki S; Kaira K; Ohshima Y; Ishioka NS; Sohda M; Yokobori T; Miyazaki T; Oriuchi N; Tominaga H; Kanai Y; Tsukamoto N; Asao T; Tsushima Y; Higuchi T; Oyama T; Kuwano H
Br J Cancer; 2014 Apr; 110(8):1985-91. PubMed ID: 24667647
[TBL] [Abstract][Full Text] [Related]
54. 18F-FAMT PET Is Useful to Distinguish between Specific Uptake and Nonspecific Uptake Compared to 18F-Flourodeoxyglucose Position Emission Tomography in Esophageal Cancer Patients.
Sohda M; Miyazaki T; Honjyo H; Hara K; Ozawa D; Sakai M; Yokobori T; Higuchi T; Tsushima Y; Kuwano H
Dig Surg; 2018; 35(5):383-388. PubMed ID: 29130979
[TBL] [Abstract][Full Text] [Related]
55. Quantitative studies using positron emission tomography (PET) for the diagnosis and therapy planning of oncological patients.
Dimitrakopoulou-Strauss A; Strauss L
Hell J Nucl Med; 2006; 9(1):10-21. PubMed ID: 16617388
[TBL] [Abstract][Full Text] [Related]
56. Differentiation of malignant and benign cardiac tumors using 18F-FDG PET/CT.
Rahbar K; Seifarth H; Schäfers M; Stegger L; Hoffmeier A; Spieker T; Tiemann K; Maintz D; Scheld HH; Schober O; Weckesser M
J Nucl Med; 2012 Jun; 53(6):856-63. PubMed ID: 22577239
[TBL] [Abstract][Full Text] [Related]
57.
Kim M; Higuchi T; Nakajima T; Andriana P; Hirasawa H; Tokue A; Kurihara J; Yokoo S; Tsushima Y
Oral Radiol; 2019 Sep; 35(3):308-314. PubMed ID: 30778900
[TBL] [Abstract][Full Text] [Related]
58. Differentiation between malignant and benign pathologic fractures with F-18-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography.
Shin DS; Shon OJ; Byun SJ; Choi JH; Chun KA; Cho IH
Skeletal Radiol; 2008 May; 37(5):415-21. PubMed ID: 18309481
[TBL] [Abstract][Full Text] [Related]
59. The role of 18F-FDG PET/CT in the metabolic characterization of lung nodules in pediatric patients with bone sarcoma.
Cistaro A; Lopci E; Gastaldo L; Fania P; Brach Del Prever A; Fagioli F
Pediatr Blood Cancer; 2012 Dec; 59(7):1206-10. PubMed ID: 22745027
[TBL] [Abstract][Full Text] [Related]
60. Glucose metabolic analysis of musculoskeletal tumours using 18fluorine-FDG PET as an aid to preoperative planning.
Watanabe H; Shinozaki T; Yanagawa T; Aoki J; Tokunaga M; Inoue T; Endo K; Mohara S; Sano K; Takagishi K
J Bone Joint Surg Br; 2000 Jul; 82(5):760-7. PubMed ID: 10963181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
